Related Experiment Video
Updated: May 10, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
RETINAL TOXICITY ASSOCIATED WITH NAB-PACLITAXEL AND GEMCITABINE WITH SBP-101
Ashley Z Zhou1, Jin Kyun Oh2, Stephen H Tsang2
1Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Purpose:
To document retinal toxicity from nab-paclitaxel and gemcitabine with SBP-101, diethyl dihydroxyhomospermine, a polyamine inhibitor for the treatment of metastatic pancreatic adenocarcinoma.
Methods:
Observational case report.
Results:
Two patients with metastatic pancreatic ductal adenocarcinoma on nab-paclitaxel and gemcitabine with SBP-101 were found to have retina pigmentary changes and retinal pigment epithelium mottling. Spectral-domain optical coherence tomography showed retinal pigment epithelium and outer retinal speckled reflectivity in the nasal and superior macula in both eyes. Subsequent follow-up visits demonstrated progression of these findings despite discontinuation of the drug. Visual acuity remained stable or slightly worsened from baseline.
Conclusion:
These cases highlight retinal toxicity of the clinical trial drug nab-paclitaxel and gemcitabine with SBP-101 and the need to monitor these patients with regular ophthalmology examinations.
